文献速递细菌感染、耐药与抗菌药物医院感染防控

碳青霉烯类抗菌药物血液学不良事件的药物警戒分析(FAERS 2013–2025)

A pharmacovigilance analysis of carbapenem-related utilizing the FDA adverse event reporting system (FAERS) database from 2013 to 2025.
PubMed 文献 · J Antimicrob Chemother · 2026-01-01

基于FAERS数据库2013年1月至2025年7月数据,采用报告比值比(ROR)及95%CI对美罗培南、厄他培南、亚胺培南和多利培南相关血液学不良事件进行不成比例分析。不同碳青霉烯类药物的血液学安全性特征存在显著差异。

要点

  • 美罗培南报告15种血液学不良事件信号,包括血小板增多症、嗜酸性粒细胞增多症、骨髓衰竭等。
  • 亚胺培南报告9种信号,突出为血小板减少症和嗜酸性粒细胞增多症。
  • 厄他培南报告9种信号,包括白细胞减少症(ROR=3.843)和中性粒细胞减少症(ROR=2.469)。

核心结论

  • 碳青霉烯类药物的血液学安全性特征存在显著差异,美罗培南表现出最广泛的重度毒性信号,其他碳青霉烯类药物报告信号较少。

研究设计与样本

  • 基于FDA不良事件报告系统(FAERS)数据库2013年1月至2025年7月数据的药物警戒分析,采用报告比值比(ROR)及95%置信区间进行不成比例分析。

主要发现

  • 美罗培南对15种不良事件显示显著信号,包括血小板增多症(ROR=24.941)、嗜酸性粒细胞增多症(ROR=24.663)、骨髓衰竭(ROR=13.113)、粒细胞缺乏症(ROR=11.57)和全血细胞减少症(ROR=11.131)。
  • 亚胺培南对9种事件显示信号, notably 血小板减少症和嗜酸性粒细胞增多症。
  • 厄他培南对9种事件显示信号,包括白细胞减少症(ROR=3.843)和中性粒细胞减少症(ROR=2.469)。
  • 多利培南未识别到报告。

临床怎么用

  • 这些差异安全性特征应为进一步研究碳青霉烯类药物选择提供信息,包括基线血液学疾病患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Carbapenem antibiotics are critical therapies for multidrug-resistant infections, but their comparative haematologic safety profiles remain poorly characterized. We systematically evaluated haematologic adverse events associated with meropenem, ertapenem, imipenem and doripenem using pharmacovigilance data. METHODS: We analyzed the FDA Adverse Event Reporting System (FAERS) database from January 2013 to July 2025. Disproportionality analysis was performed using reporting odds ratios (RORs) with 95% confidence intervals for haematologic adverse events. RESULTS: Sixteen distinct haematologic adverse events were identified. Meropenem demonstrated the most extensive toxicity profile with significant signals for 15 adverse events, including severe conditions: thrombocytosis (ROR = 24.941), eosinophilia (ROR = 24.663), bone marrow failure (ROR = 13.113), agranulocytosis (ROR = 11.57) and pancytopenia (ROR = 11.131). Imipenem demonstrated signals for nine events, notably thrombocytopenia and eosinophilia. Ertapenem demonstrated nine events: leucopenia (ROR = 3.843) and neutropenia (ROR = 2.469). No reports were identified for doripenem. CONCLUSIONS: Significant differences exist in haematologic safety profiles among carbapenems. Meropenem shows the broadest spectrum of severe toxicity, while other carbapenems demonstrate fewer reports. demonstrates fewer reported haematologic safety signals and not a most favourable haematologic safety profile. These differential safety profiles should inform further studies on carbapenem selection, including patients with baseline haematologic disorders.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Frey C, Elmi P. A pharmacovigilance analysis of carbapenem-related utilizing the FDA adverse event reporting system (FAERS) database from 2013 to 2025. J Antimicrob Chemother. 2026. PMID: 41718700. doi:10.1093/jac/dkag060

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。